Cancer Therapeutics CRC Pty Ltd - Product Pipeline Review - 2013


#171320

37pages

Global Markets Direct

$ 1500

In Stock


Global Market Directs pharmaceuticals report, Cancer Therapeutics CRC Pty Ltd Product Pipeline Review 2013 provides data on the Cancer Therapeutics CRC Pty Ltds research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Cancer Therapeutics CRC Pty Ltds corporate website, SEC filings, investor presentations and featured press releases, both from Cancer Therapeutics CRC Pty Ltd and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • Cancer Therapeutics CRC Pty Ltd Brief Cancer Therapeutics CRC Pty Ltd overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Cancer Therapeutics CRC Pty Ltd human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Cancer Therapeutics CRC Pty Ltd with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Cancer Therapeutics CRC Pty Ltds pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Cancer Therapeutics CRC Pty Ltds strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Cancer Therapeutics CRC Pty Ltd in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Cancer Therapeutics CRC Pty Ltds R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Cancer Therapeutics CRC Pty Ltd.
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Cancer Therapeutics CRC Pty Ltd and identify potential opportunities in those areas.